BIOS: Nucleus of Life Science Innovation 🚀
JOBS
BIOS Talent: Find Jobs @ Breakout TechBio Startups — Search Jobs 🚀
Post Jobs: Add Your Startup to BIOS Talent — Post Now 🎉
Students: Join Alix Ventures Fellowship — Join Now 🧬
BIOS Contributor: Share Your Thought Leadership — Join Now🔬
CONTENT & COMMUNITY
BIOS Daily: Join 25K+ Subscribers Following TechBio — Sign Up 🔥
BIOS Insider: Premium TechBio Thought Leadership — Sign Up ✨
BIOS Commons: World’s Largest #TechBio Community — Join Now 🎉
INVEST
BIOS Angels: 1st TechBio Angel Investing Syndicate — Join Now 🌟
Alix Limited: Invest in Breakout TechBio Startups — Learn More 🧠
By:
Alix Ventures: Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health
Overview
Organoids have emerged as a potential solution to many challenges in early-stage drug development and have the potential to reduce costs while improving translation of pre-clinical safety and efficacy studies. More recent advances in the space have also opened the possibility of using organoids as part of regenerative medicine or precision medicine therapies. At a high level, organoids are 3-dimensional cell cultures meant to mimic the micro anatomy and behavior of human organs. Formally, they are defined as self-organizing 3D structures grown from stem cells that mimic the in vivo environment, architecture and multi-lineage differentiation of the original organoids. They can be established from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), collectively known as PSC-derived organoids, or from adult stem cells (ASCs) which are obtained by resection or biopsy of organs from donors. Generally, they are grown in a cell culture plate or bioreactor and begin to resemble the desired structure of the desired tissue type in ~3 weeks.